Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
Abstract Background Ruxolitinib improves splenomegaly and symptoms in patients with intermediate-2 or high-risk myelofibrosis; however, nearly half develop grade 3/4 anemia and/or thrombocytopenia, necessitating dose reductions and/or transfusions. We report findings from an open-label phase 2 study...
Na minha lista:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMC
2018-08-01
|
| coleção: | Journal of Hematology & Oncology |
| Assuntos: | |
| Acesso em linha: | http://link.springer.com/article/10.1186/s13045-018-0642-0 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|